Adagene Inc.
ADAG
NASDAQ·Healthcare·Biotechnology·Mkt cap $134.8M
$3.58
▼ -2.98%
P/E
-2.32
Mkt Cap
$134.8M
52-Wk Range
$1.30–$4.85
52-Week Range
$1.30 - $4.85
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 49.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Revenue decline expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+7.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ADAG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
AUG 12, 2026
Reported EPS of -$0.23 vs -$0.23 consensus (0.0% surprise). Revenue of $1.6M vs $1.6M expected (0.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
—
—
-100%
-75%
-100%
—
—
Q3 23
Q4 23
Q1 24
Q2 24
Q4 24
Q2 25
Q4 25
Q2 26
$407.9K
$407.9K
$0
$0
$103.2K
$0
$7.7M
$1.6M
Margins · last 8Q
Gross
84.2%
Operating
—
Profit
-1011.1%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Jul 14, 2026
vs Industry
How ADAG stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.